11 results
SC14D9C
EX-99.4
DBTX
Decibel Therapeutics, Inc.
9 Aug 23
Written communication relating to third party tender offer
4:55pm
].
This is a momentous event for Decibel which will provide extensive support and resources to deliver on our mission to create innovative medicines
SC TO-C
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
9 Aug 23
Information about tender offer
4:15pm
to approximately $213 million if the CVR milestones are achieved.
“We at Decibel are deeply committed to discovering and advancing innovative new therapies … and specialized team will further strengthen our genetic medicines portfolio, enabling Regeneron to accelerate the development of innovative genetic therapies
8-K
EX-99.2
DBTX
Decibel Therapeutics, Inc.
9 Aug 23
Tender and Support Agreement
8:02am
to approximately $213 million if the CVR milestones are achieved.
“We at Decibel are deeply committed to discovering and advancing innovative new therapies … and specialized team will further strengthen our genetic medicines portfolio, enabling Regeneron to accelerate the development of innovative genetic therapies
10-K
2020 FY
DBTX
Decibel Therapeutics, Inc.
29 Mar 21
Annual report
5:08pm
disorders by discovering, developing and commercializing innovative gene therapies for restoration and regeneration of hair cells and non-sensory support … innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Manufacturers must
424B4
cclzflxo8oswe ywq
12 Feb 21
Prospectus supplement with pricing info
4:30pm
S-1/A
sthdlqapzzx3vq4 9qw
28 Jan 21
IPO registration (amended)
5:02pm
S-1
827 q9i7dlw4l0e8if
22 Jan 21
IPO registration
4:42pm
DRS/A
i18qb7p
12 Jan 21
Draft registration statement (amended)
12:00am
DRS
rmia2 3r7mrx
11 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next